Land: Sør-Afrika
Språk: engelsk
Kilde: South African Health Products Regulatory Authority (SAHPRA)
Lennon
INDICATIONS [/za_1269.html#1] [/za_1269.html#1] [/za_1269.html#1] CONTRA-INDICATIONS [/za_1269.html#1] [/za_1269.html#1] DOSAGE [/za_1269.html#1] [/za_1269.html#1] SIDE-EFFECTS [/za_1269.html#1] [/za_1269.html#1] [/za_1269.html#1] PREGNANCY [/za_1269.html#1] [/za_1269.html#1] OVERDOSE [/za_1269.html#1] IDENTIFICATION [/za_1269.html#1] [/za_1269.html#1] PATIENT INFORMATION HYPOMIDE®-100 TABLETS HYPOMIDE®-250 TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): HYPOMIDE ® -100 TABLETS HYPOMIDE ® -250 TABLETS COMPOSITION: Each tablet contains CHLORPROPAMIDE 100 mg or 250 mg. PHARMACOLOGICAL CLASSIFICATION: A 21.2 Oral Hypoglycaemics. PHARMACOLOGICAL ACTION: The mode of action of chlorpropamide is believed to be that of stimulation of the synthesis and release of endogenous insulin. There is evidence that improvement in pancreatic beta cell function, with consequent improvement in glucose tolerance may occur with prolonged administration of chlorpropamide. INDICATIONS: Chlorpropamide is indicated in uncomplicated diabetes mellitus of the stable, mild or moderately severe, non-ketotic, maturity-onset type, which cannot be controlled by diet alone. Patients should be carefully selected for chlorpropamide therapy. Evaluation of response in patients who qualify as candidates for chlorpropamide is a therapeutic trial for a period of at least seven days. During the trial period, the absence of ketonuria together with a satisfactory reduction of glycosuria and hyperglycemia, or maintenance of previously satisfactory control, indicates that the patient is responsive and amendable to control with the drug. However, the development of ketonuria within 24 hours after withdrawal of insulin usually will be indicative of a poor response. The patient is considered non-res Les hele dokumentet